Nordea Investment Management AB Acquires Shares of 20,008 Insmed, Inc. $INSM

Nordea Investment Management AB acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 20,008 shares of the biopharmaceutical company’s stock, valued at approximately $3,492,000.

Several other hedge funds and other institutional investors also recently modified their holdings of INSM. CIBC Private Wealth Group LLC increased its holdings in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the period. Kingsview Wealth Management LLC increased its stake in Insmed by 2.7% in the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the period. Choreo LLC raised its position in Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 65 shares during the last quarter. Spire Wealth Management lifted its stake in shares of Insmed by 11.5% in the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 80 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 81 shares during the period.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 748 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. This represents a 0.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Roger Adsett sold 791 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the sale, the chief operating officer owned 106,810 shares in the company, valued at approximately $16,680,517.70. This represents a 0.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 189,651 shares of company stock worth $31,533,654 over the last quarter. Insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

INSM has been the topic of a number of recent analyst reports. The Goldman Sachs Group boosted their price target on shares of Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. HC Wainwright lifted their price objective on Insmed from $230.00 to $245.00 and gave the company a “buy” rating in a report on Thursday. Citigroup reiterated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Rothschild & Co Redburn set a $263.00 target price on Insmed in a research note on Thursday, December 4th. Finally, Guggenheim reduced their price target on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $210.19.

Insmed Stock Down 1.6%

Shares of NASDAQ INSM opened at $145.30 on Friday. The stock has a market capitalization of $31.32 billion, a price-to-earnings ratio of -22.67 and a beta of 1.13. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The firm has a 50-day moving average price of $150.13 and a 200 day moving average price of $165.97. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the previous year, the company posted ($1.32) earnings per share. The company’s quarterly revenue was up 152.6% compared to the same quarter last year. Equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.